Matthew Fust

Matthew K.
Fust is currently an Independent Director at Ultragenyx Pharmaceutical, Inc. since 2014, Atara Biotherapeutics, Inc. since 2014, Crinetics Pharmaceuticals, Inc. since 2018, and Neumora Therapeutics, Inc. since 2020.
Mr. Fust is also a Director at Arsenal Biosciences, Inc. since 2021.
Former roles include Independent Director at Sunesis Pharmaceuticals, Inc. from 2011 to 2017, MacroGenics, Inc. from 2014 to 2020, and Dermira, Inc. from 2014 to 2020.
Mr. Fust was Director at BlackThorn Therapeutics, Inc. from 2017 to 2020.
Held the position of Chief Financial Officer & Senior Vice President at ALZA Corp.
from 1996 to 2002, Chief Financial Officer at Perlegen Sciences, Inc. from 2002 to 2003, Chief Financial Officer & Executive Vice President at Jazz Pharmaceuticals, Inc. from 2003 to 2008, Executive Vice President-Finance at Onyx Pharmaceuticals, Inc. from 2013 to 2014, and Manager-Healthcare Strategy Practice at Anderson Consulting Team in 1996.
Education includes an undergraduate degree from the University of Minnesota in 1986 and an MBA from Stanford Graduate School of Business in 1991.